← All Conmed CORP filings

Conmed CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
CNMD
Conmed CORP
10-K: CONMED Reports 5.2% Sales Growth, Strategic Shifts
CONMED Corporation reported a 5.2% increase in net sales for 2025, driven by growth in orthopedic and general surgery, alongside strategic portfolio optimization and a dividend suspension.
NYSE
CNMD
Conmed CORP
10-K: CONMED Corporation Reports Increased Net Sales in 2024 Annual Report
CONMED Corporation's 2024 annual report reveals a 5.0% increase in net sales, driven by growth in both orthopedic and general surgery product lines.
NYSE
CNMD
Conmed CORP
10-K: CONMED Corporation Outlines Common Stock Details and Anti-Takeover Measures in 10-K Filing
CONMED Corporation's 10-K filing details the terms of its common stock, including dividend, voting, and liquidation rights, as well as anti-takeover provisions.